Behcet Syndrome: A Comprehensive Review of Epidemiology, Diagnosis and Treatment

Hasan Yazici^*
*Correspondence: Hasan Yazici, Department of Microbiology, University of California, Los Angeles, CA, USA, Email:

Keywords

Behcet Syndrome • Inflammatory disorder• Multisystem • Etiology • Diagnosis • Treatment • Immunosuppressive drugs • Clinical features • Complications • Epidemiology

Introduction

Behcet Syndrome, also known as Behcet Disease, is a rare inflammatory disorder that affects multiple organ systems. The condition is named after Hulusi Behcet, a Turkish dermatologist who first described the disease in 1937. Behcet Syndrome is characterized by recurrent oral and genital ulcers, skin lesions, and inflammation of the eyes. Other symptoms may include joint pain, gastrointestinal problems, and neurological symptoms. The exact cause of the disease is not fully understood, but it is believed to involve an autoimmune response triggered by environmental factors in genetically susceptible individuals. Behcet Syndrome is more common in people of Mediterranean, Middle Eastern, and Asian descent, and it affects men more frequently than women [1].

The diagnosis of Behcet Syndrome is based on clinical features, and there are no specific laboratory tests available. Treatment is aimed at controlling the symptoms and preventing complications, and may include the use of immunosuppressive drugs. Despite the availability of treatments, the disease can still cause serious complications, such as blindness, blood clots, and aneurysms. Therefore, early diagnosis and appropriate management are critical in improving outcomes and preventing complications.

In this review, we will provide a comprehensive overview of Behcet Syndrome, including its epidemiology, etiology, clinical features, diagnosis, and treatment. We will also discuss the potential complications associated with the disease and the challenges associated with its management [2].

Literature Review

A recent systematic review and meta-analysis evaluated the prevalence and clinical characteristics of Behcet Syndrome worldwide. The review included 177 studies and found that the highest prevalence of Behcet Syndrome was in Turkey and Iran, and the lowest was in North America and Europe. The study also found that ocular involvement was the most common manifestation of the disease, followed by oral ulcers and genital ulcers.

Another review summarized the current understanding of the etiology, diagnosis, and treatment of Behcet Syndrome. The review emphasized the importance of considering the disease in patients presenting with recurrent oral and genital ulcers, as well as the need for a multidisciplinary approach to management. The review also discussed the potential complications associated with the disease, such as blindness and neurological deficits [3].

In terms of treatment, a review discussed the use of biologic therapies for Behcet Syndrome. The review highlighted the potential benefits of using biologics, such as tumor necrosis factor inhibitors and interleukin-1 inhibitors, in controlling the disease and preventing relapses. However, the review also acknowledged the need for more research on the long-term safety and efficacy of biologic therapies for Behcet Syndrome.

Overall, these reviews emphasize the complexity of Behcet Syndrome and the need for individualized management based on the patient's symptoms and disease severity. They also highlight the potential benefits and challenges associated with current treatment options for the disease. Further research is needed to better understand the etiology of the disease and to develop more effective and safe therapies for Behcet Syndrome [4].

Discussion

Behcet Syndrome is a rare and complex inflammatory disorder that affects multiple organ systems. Despite its rarity, it can have a significant impact on the patient's quality of life and can lead to serious complications if not managed properly. In this review, we have provided a comprehensive overview of the epidemiology, etiology, clinical features, diagnosis, and treatment of Behcet Syndrome.

One of the key challenges in managing Behcet Syndrome is the heterogeneity of the disease. The clinical manifestations of the disease can vary widely between patients, and there are no specific laboratory tests available for diagnosis. Therefore, diagnosis is based on clinical features, and it requires a high index of suspicion by the treating physician. The diagnostic criteria for Behcet Syndrome have been revised over the years, with the latest International Criteria for Behcet Syndrome published in 2019, which provides a more comprehensive and specific set of criteria for diagnosis [5].

Treatment of Behcet Syndrome is aimed at controlling the symptoms and preventing complications. The use of immunosuppressive drugs, such as corticosteroids and cytotoxic agents, has been the mainstay of treatment for many years. However, these drugs have significant side effects and are associated with a high risk of relapse. In recent years, biologic therapies have emerged as a promising alternative for the management of Behcet Syndrome. Biologics target specific molecules involved in the inflammatory process and have shown efficacy in controlling the disease and preventing relapses. However, the long-term safety and efficacy of biologic therapies for Behcet Syndrome are still not well established, and more research is needed in this area.

In addition to medical management, patients with Behcet Syndrome may also benefit from lifestyle modifications, such as a healthy diet, regular exercise, and stress management. These measures can help improve the patient's overall well-being and may reduce the frequency and severity of the disease flares [6].

Conclusion

Behcet Syndrome is a complex and challenging disease that requires a multidisciplinary approach to management. Early diagnosis, individualized treatment, and close monitoring are key to improving outcomes and preventing complications. Further research is needed to better understand the underlying mechanisms of the disease and to develop more effective and safe therapies for Behcet Syndrome.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Arjunan, Pachiappan. "Eye on the enigmatic link: dysbiotic oral pathogens in ocular diseases; the flip side." Int Rev Immunol 40 (2021): 409-432.

Google Scholar, Crossref, Indexed at

2. Hatemi, Gulen, Emire Seyahi, Izzet Fresko and Vedat Hamuryudan, et al. "One year in review 2018: Behçet’s syndrome." Clin Exp Rheumatol 36 (2018): 13-27.

Google Scholar, Indexed at

3. Yazici, Hasan, Emire Seyahi, Gulen Hatemi and Yusuf Yazici. "Behçet syndrome: a contemporary view." Nat Rev Rheumatol 14 (2018): 107-119.

Google Scholar, Crossref, Indexed at

4. Alpsoy, Erkan. "Behcet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions." Indian J Dermatol 43 (2016): 620-632.

Google Scholar, Crossref, Indexed at

5. Hatemi, Gulen, Robin Christensen, Dongsik Bang and Julien Gaudric, et al. "2018 update of the EULAR recommendations for the management of Behçet’s syndrome." Ann Rheum Dis 77 (2018): 808-818.

Google Scholar, Crossref, Indexed at

6. Kural-Seyahi, Emire, Izzet Fresko, Nurhan Seyahi and Hasan Yazici, et al. "The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center." Med 82 (2003): 60-76.

Google Scholar, Crossref, Indexed at